🟢 Neurosense Therapeutics is trading 5.16% up in pre-market with no confirmed fresh catalyst

Neurosense Therapeutics is trading 5.16% up in pre-market at $0.40, after closing at $0.38 on August 21, 2026, with no confirmed fresh catalyst identified.

• No new company-specific announcement dated August 24, 2026, was identified in available overnight coverage.
• Shareholders will vote August 26 on a potential 1-for-4 to 1-for-40 reverse split.
• An August 13 CEO letter discussed Phase 3 ALS plans and Nasdaq compliance efforts.